Similar articles

• Pathogenetic aspects of uremic cardiomyopathy.

  Coratelli P, Buongiorno E, Petrarulo F, Corciulo R, Giannattasio M, Passavanti G, Antonelli G. Coratelli P, et al. Miner Electrolyte Metab. 1989;15(4):246-53. Miner Electrolyte Metab. 1989. PMID: 2761492
• αKlotho attenuates cardiac hypertrophy and increases myocardial fibroblast growth factor 21 expression in uremic rats.

  Suassuna PGA, Cherem PM, de Castro BB, Maquigussa E, Cenedeze MA, Lovisi JCM, Custódio MR, Sanders-Pinheiro H, de Paula RB. Suassuna PGA, et al. Exp Biol Med (Maywood). 2020 Jan;245(1):66-78. doi: 10.1177/1535370219894302. Epub 2019 Dec 17. Exp Biol Med (Maywood). 2020. PMID: 31847589 Free PMC article.
• Low-dose growth hormone is cardioprotective in uremia.

  Rabkin R, Awwad I, Chen Y, Ashley EA, Sun D, Sood S, Clusin W, Heidenreich P, Piecha G, Gross ML. Rabkin R, et al. J Am Soc Nephrol. 2008 Sep;19(9):1774-83. doi: 10.1681/ASN.2007121386. Epub 2008 Jul 23. J Am Soc Nephrol. 2008. PMID: 18650479 Free PMC article.
• Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.

  Gross ML, Ritz E. Gross ML, et al. Semin Dial. 2008 Jul-Aug;21(4):308-18. doi: 10.1111/j.1525-139X.2008.00454.x. Epub 2008 Jul 8. Semin Dial. 2008. PMID: 18627569 Review.
• Uremic rat model: experience with young rats.

  Kleinknecht C, Laouari D, Burtin M. Kleinknecht C, et al. Contrib Nephrol. 1988;60:27-38. doi: 10.1159/000414787. Contrib Nephrol. 1988. PMID: 3278859 Review. No abstract available.